Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
Sight Sciences reported that President and CEO Paul Badawi received a grant of 154,560 restricted stock units on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant’s size is based on a $1,000,000 value divided by the stock’s closing price on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Badawi’s continued service. Following this award, he beneficially owns 6,180,400 shares of common stock, including 662,622 shares underlying unvested RSUs.
Sight Sciences Chief Financial Officer James Rodberg received a grant of 86,940 restricted stock units (RSUs) of common stock on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is set at $562,500, divided by the stock’s closing price on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Rodberg’s continued service. Each RSU converts into one share of common stock upon vesting. After this award, he beneficially owns 238,170 shares, including 198,719 unvested RSUs and 39,451 vested shares.
Sight Sciences executive Brenton Taylor reported a new equity award. As EVP, Operations & R&D, he received 100,464 restricted stock units (RSUs) on February 3, 2026 under the company’s 2021 Incentive Award Plan, recorded as an acquisition of common stock at a price of $0 per share.
The grant size is based on dividing $650,000 by the closing price of Sight Sciences common stock on the grant date. These RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. After this award, he beneficially owns 270,676 shares, including 26,606 shares of common stock and 244,070 shares that will be acquired upon future RSU vesting and settlement.
KCK Ltd. and Nael Karim Kassar report beneficial ownership of 3,706,914 shares of Sight Sciences, Inc. common stock, representing 7.0% of the class. The stake relates to an event dated 12/31/2025 and is reported on Amendment No. 3 to a Schedule 13G.
The ownership percentage is calculated using 52,871,731 shares of common stock outstanding as of October 31, 2025, as disclosed in Sight Sciences’ Form 10-Q for the quarter ended September 30, 2025. All voting and dispositive powers over these shares are reported as shared, with no sole voting or dispositive authority.
Sight Sciences, Inc. entered into a Second Amendment to its multi-tenant space lease for its headquarters at 4040 Campbell Avenue, Menlo Park, California. The amendment, signed with Deerfield Campbell, LLC, extends the existing lease term by 26 months, starting on November 1, 2026 and ending on December 31, 2028.
Under the extension, base monthly rent is fully abated from November 1, 2026 through December 31, 2026. Rent is then set at $44,915.45 per month from January 1, 2027 through October 31, 2027, $46,214.21 per month from November 1, 2027 through October 31, 2028, and $47,621.20 per month from November 1, 2028 through December 31, 2028.
Sight Sciences, Inc. director and Chief Technology Officer David Badawi reported a small insider sale of company stock. On January 16, 2026, he sold 4,836 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability in connection with the vesting of restricted stock units.
After this transaction, Badawi beneficially owns a total of 1,912,273 shares of Sight Sciences common stock, consisting of 1,774,250 shares of common stock and 138,023 shares that will be acquired upon the vesting and settlement of unvested restricted stock units.
Sight Sciences, Inc. Chief Financial Officer James Rodberg reported a small sale of company stock on January 16, 2026. He sold 2,616 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability arising from the vesting of restricted stock units. The shares were sold in multiple trades at prices ranging from $6.44 to $6.69.
After this transaction, Rodberg beneficially owned 151,230 shares, consisting of 39,451 shares of common stock and 111,779 shares that will be received upon future vesting and settlement of restricted stock units.
Sight Sciences, Inc. President and CEO Paul Badawi, who is also a director and 10% owner, reported selling 22,362 shares of common stock on January 16, 2026 at a weighted average price of $6.62 per share. According to the filing, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi beneficially owns 6,025,840 shares of Sight Sciences common stock. This total includes 5,517,778 shares of common stock and 508,062 shares that will be received upon the vesting and settlement of unvested RSUs. The balance also corrects prior Form 4 reports by adding previously omitted RSUs and excluding certain stock option shares that were mistakenly included earlier.
Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 6,308 shares of the company’s common stock on January 16, 2026 at a weighted average price of $6.62 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units, rather than as a discretionary open-market sale. Following this transaction, he beneficially owns 267,611 shares, consisting of 75,562 shares of common stock and 192,049 shares that will be received upon vesting and settlement of unvested RSUs. The filing also clarifies prior reporting by adding 39,825 previously omitted RSU shares and removing 11,326 stock option shares that had been inadvertently included in an earlier balance.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Sight Sciences, Inc. common stock. As of the event date of December 31, 2025, BlackRock reports beneficial ownership of 2,651,156 shares, representing 5.01% of Sight Sciences’ outstanding common stock.
BlackRock reports sole voting power over 2,614,209 shares and sole dispositive power over 2,651,156 shares, with no shared voting or dispositive power. The filing notes that various underlying persons have rights to dividends or sale proceeds in the ordinary course, but no single person has more than five percent of the total outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Sight Sciences, consistent with a passive institutional investment.